Second European Stelara Biosimilar Pits Sandoz Against Stada

Sandoz Launches Samsung Bioepis-Partnered Pyzchiva Ustekinumab Rival Across Europe

 
• By Dave Wallace

Just days after the first European ustekinumab biosimilar launch, Sandoz has entered the fray with the second rival to Stelara, introducing its Samsung Bioepis-partnered Pyzchiva version to compete with Stada and Alvotech’s Uzpruvo.

Player One vs Player Two graphic
Sandoz and Stada are facing off in Europe over ustekinumab • Source: Shutterstock

More from Biosimilars

More from Products